## Stephan von HĶrsten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/674098/publications.pdf

Version: 2024-02-01

189 papers 7,896 citations

44042 48 h-index 78 g-index

203 all docs

203 docs citations

203 times ranked 9430 citing authors

#	Article	IF	CITATIONS
1	N471D WASH complex subunit strumpellin knockâ€in mice display mild motor and cardiac abnormalities and BPTF and KLHL11 dysregulation in brain tissue. Neuropathology and Applied Neurobiology, 2022, 48, ·	1.8	4
2	Microvascular development in the rat arteriovenous loop model in vivoâ€"A step by step intravital microscopy analysis. Journal of Biomedical Materials Research - Part A, 2022, , .	2.1	4
3	The difficulty to model Huntington's disease in vitro using striatal medium spiny neurons differentiated from human induced pluripotent stem cells. Scientific Reports, 2021, 11, 6934.	1.6	17
4	CD161a-positive natural killer (NK) cells and $\hat{l}\pm$ -smooth muscle actin-positive myofibroblasts were upregulated by extrarenal DPP4 in a rat model of acute renal rejection. Diabetes Research and Clinical Practice, 2021, 173, 108691.	1.1	2
5	Prenatally traumatized mice reveal hippocampal methylation and expression changes of the stress-related genes Crhr1 and Fkbp5. Translational Psychiatry, 2021, 11, 183.	2.4	6
6	Human alpha-synuclein overexpressing MBP29 mice mimic functional and structural hallmarks of the cerebellar subtype of multiple system atrophy. Acta Neuropathologica Communications, 2021, 9, 68.	2.4	9
7	Proteolytic α-Synuclein Cleavage in Health and Disease. International Journal of Molecular Sciences, 2021, 22, 5450.	1.8	15
8	Watching the Vessels Grow: Establishment of Intravital Microscopy in the Arteriovenous Loop Rat Model. Tissue Engineering - Part C: Methods, 2021, 27, 357-365.	1.1	4
9	A glutaminyl cyclase-catalyzed $\hat{l}\pm$ -synuclein modification identified in human synucleinopathies. Acta Neuropathologica, 2021, 142, 399-421.	3.9	13
10	Transglutaminase 6 Is Colocalized and Interacts with Mutant Huntingtin in Huntington Disease Rodent Animal Models. International Journal of Molecular Sciences, 2021, 22, 8914.	1.8	6
11	Lung development and immune status under chronic LPS exposure in rat pups with and without CD26/DPP4 deficiency. Cell and Tissue Research, 2021, 386, 617-636.	1.5	1
12	A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Molecular Psychiatry, 2020, 25, 2101-2118.	4.1	59
13	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 137-149.	2.9	75
14	Postnatal morphological lung development of wild type and CD26/DPP4 deficient rat pups in dependency of LPS exposure. Annals of Anatomy, 2020, 229, 151423.	1.0	6
15	Compensatory neuritogenesis of serotonergic afferents within the striatum of a transgenic rat model of Parkinson's disease. Brain Research, 2020, 1748, 147119.	1.1	6
16	Myeloperoxidase Modulates Inflammation in Generalized Pustular Psoriasis and Additional Rare Pustular Skin Diseases. American Journal of Human Genetics, 2020, 107, 527-538.	2.6	53
17	A Sphingosine-1-Phosphate Receptor Modulator Attenuated Secondary Brain Injury and Improved Neurological Functions of Mice after ICH. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-8.	1.9	6
18	Imbalance of the oxytocin-vasopressin system contributes to the neuropsychiatric phenotype in the BACHD mouse model of Huntington disease. Psychoneuroendocrinology, 2020, 119, 104773.	1.3	8

#	Article	IF	CITATIONS
19	Thirty Mouse Strain Survey of Voluntary Physical Activity and Energy Expenditure: Influence of Strain, Sex and Day–Night Variation. Frontiers in Neuroscience, 2020, 14, 531.	1.4	11
20	Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro. Molecules, 2020, 25, 580.	1.7	53
21	Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats. Scientific Reports, 2020, 10, 22385.	1.6	13
22	Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. Journal of Clinical Investigation, 2020, 130, 2509-2526.	3.9	29
23	Systematic data analysis and data mining in CatWalk gait analysis by heat mapping exemplified in rodent models for neurodegenerative diseases. Journal of Neuroscience Methods, 2019, 326, 108367.	1.3	14
24	Differential Levels and Phosphorylation of Type 1 Inositol 1,4,5-Trisphosphate Receptor in Four Different Murine Models of Huntington Disease. Journal of Huntington's Disease, 2019, 8, 271-289.	0.9	2
25	Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage. Stroke, 2019, 50, 3246-3254.	1.0	34
26	Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 79.	2.4	5
27	Disrupted-in-Schizophrenia 1 (DISC1) Overexpression and Juvenile Immune Activation Cause Sex-Specific Schizophrenia-Related Psychopathology in Rats. Frontiers in Psychiatry, 2019, 10, 222.	1.3	15
28	Role of hypothalamus-pituitary-adrenal axis modulation in the stress-resilient phenotype of DPP4-deficient rats. Behavioural Brain Research, 2019, 356, 243-249.	1.2	10
29	Treadmill exercise intervention improves gait and postural control in alpha-synuclein mouse models without inducing cerebral autophagy. Behavioural Brain Research, 2019, 363, 199-215.	1.2	27
30	Differential severity of LPS-induced lung injury in CD26/DPP4 positive and deficient F344 rats. Histology and Histopathology, 2019, 34, 1151-1171.	0.5	4
31	Silhouette-Length-Scaled Gait Parameters for Motor Functional Analysis in Mice and Rats. ENeuro, 2019, 6, ENEURO.0100-19.2019.	0.9	12
32	Dynamic footprint based locomotion sway assessment in α-synucleinopathic mice using Fast Fourier Transform and Low Pass Filter. Journal of Neuroscience Methods, 2018, 296, 1-11.	1.3	15
33	A13â€Expression of FKBP51 and HAP40 protein in a congenic rat model of huntington disease. , 2018, , .		O
34	Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. European Neuropsychopharmacology, 2018, 28, 1382-1393.	0.3	8
35	Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8765-E8774.	3.3	47
36	Dynamic footprints of $\hat{l}$ ±-synucleinopathic mice recorded by CatWalk gait analysis. Data in Brief, 2018, 17, 189-193.	0.5	7

#	Article	IF	Citations
37	Early Alterations in Operant Performance and Prominent Huntingtin Aggregation in a Congenic F344 Rat Line of the Classical CAGn51trunc Model of Huntington Disease. Frontiers in Neuroscience, 2018, 12, 11.	1.4	5
38	A20â€A role for transglutaminase 6 in hd pathology. , 2018, , .		O
39	I19â€Normalization of phenotype and reduction of gliosis levels via glutaminyl cyclases inhibition in a huntington disease mouse model. , 2018, , .		O
40	Novel role of NPY in neuroimmune interaction and lung growth after intrauterine growth restriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L491-L506.	1.3	17
41	Capturing schizophrenia-like prodromal symptoms in a spinocerebellar ataxia-17 transgenic rat. Journal of Psychopharmacology, 2017, 31, 461-473.	2.0	5
42	Impaired Decision Making and Loss of Inhibitory-Control in a Rat Model of Huntington Disease. Frontiers in Behavioral Neuroscience, 2016, 10, 204.	1.0	23
43	Neuropeptide Y ( <scp>NPY</scp> ) in cerebrospinal fluid from patients with Huntington's Disease: increased <scp>NPY</scp> levels and differential degradation of the <scp>NPY</scp> <sub>1–30</sub> fragment. Journal of Neurochemistry, 2016, 137, 820-837.	2.1	17
44	Effects of <i>In utero</i> environment and maternal behavior on neuroendocrine and behavioral alterations in a mouse model of prenatal trauma. Developmental Neurobiology, 2016, 76, 1254-1265.	1.5	21
45	Combining Classical Comprehensive with Ethological Based, High-Throughput Automated Behavioral Phenotyping for Rodent Models of Stroke. Neuromethods, 2016, , 243-261.	0.2	3
46	Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clinical and Experimental Immunology, 2016, 185, 1-21.	1.1	332
47	Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Clinical and Experimental Immunology, 2016, 184, 265-283.	1.1	87
48	Differential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor proteinâ€specific antibodies. Aging Cell, 2016, 15, 953-963.	3.0	22
49	IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes. Biological Chemistry, 2016, 397, 45-55.	1.2	23
50	In situ enzymatic activity of transglutaminase isoforms on brain tissue sections of rodents: A new approach to monitor differences in post-translational protein modifications during neurodegeneration. Brain Research, 2016, 1631, 22-33.	1.1	2
51	Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation. Neuropeptides, 2016, 57, 21-34.	0.9	35
52	FDG μPET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study. Journal of Huntington's Disease, 2015, 4, 37-47.	0.9	2
53	Proteolytic degradation of neuropeptide Y ( <scp>NPY</scp> ) from head to toe: Identification of novel <scp>NPY</scp> â€eleaving peptidases and potential drug interactions in <scp>CNS</scp> and Periphery. Journal of Neurochemistry, 2015, 135, 1019-1037.	2.1	28
54	Reduction in Subventricular Zone-Derived Olfactory Bulb Neurogenesis in a Rat Model of Huntington's Disease Is Accompanied by Striatal Invasion of Neuroblasts. PLoS ONE, 2015, 10, e0116069.	1.1	34

#	Article	IF	CITATIONS
55	DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY. Psychoneuroendocrinology, 2015, 53, 195-206.	1.3	20
56	Myofibrillar instability exacerbated by acute exercise in filaminopathy. Human Molecular Genetics, 2015, 24, 7207-7220.	1.4	50
57	FDG μPET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study. Journal of Huntington's Disease, 2015, 4, 37-47.	0.9	2
58	<scp>DPP</scp> 4 Inhibitors increase differentially the expression of surfactant proteins in Fischer 344 rats. Acta Physiologica, 2014, 212, 248-261.	1.8	9
59	Maternal Deprivation Decelerates Postnatal Morphological Lung Development of F344 Rats. Anatomical Record, 2014, 297, 317-326.	0.8	7
60	Differential OVA-induced pulmonary inflammation and unspecific reaction in Dark Agouti (DA) rats contingent on CD26/DPPIV deficiency. Immunobiology, 2014, 219, 888-900.	0.8	1
61	Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington's disease. Journal of Neuroscience Methods, 2014, 234, 38-53.	1.3	45
62	Peritoneal exudate cells from long-lived rats exhibit increased IL-10/IL- $1\hat{l}^2$ expression ratio and preserved NO/urea ratio following LPS-stimulation in vitro. Age, 2014, 36, 9696.	3.0	6
63	Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides, 2014, 57, 109-117.	1.2	56
64	From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience and Biobehavioral Reviews, 2013, 37, 138-151.	2.9	275
65	Altered diffusion tensor imaging measurements in aged transgenic Huntington disease rats. Brain Structure and Function, 2013, 218, 767-778.	1.2	19
66	Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration. BMC Neuroscience, 2013, 14, 108.	0.8	22
67	Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: a matter of dose, route, and time. Physiological Reports, 2013, 1, e00095.	0.7	23
68	Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington's disease. Behavioural Brain Research, 2013, 239, 15-26.	1.2	23
69	Transgenic Rat Models of Huntington's Disease. Current Topics in Behavioral Neurosciences, 2013, 22, 135-147.	0.8	18
70	Modified impact of emotion on temporal discrimination in a transgenic rat model of Huntington disease. Frontiers in Behavioral Neuroscience, 2013, 7, 130.	1.0	17
71	Early cognitive dysfunction in the HD 51 CAG transgenic rat model of Huntington's disease Behavioral Neuroscience, 2012, 126, 479-487.	0.6	18
72	Early Postnatal Hyperalimentation Impairs Renal Function via SOCS-3 Mediated Renal Postreceptor Leptin Resistance. Endocrinology, 2012, 153, 1397-1410.	1.4	22

#	Article	IF	CITATIONS
73	Automated Behavioral Phenotyping Reveals Presymptomatic Alterations in a SCA3 Genetrap Mouse Model. Journal of Genetics and Genomics, 2012, 39, 287-299.	1.7	15
74	Memory deficits in the transgenic rat model of Huntington's disease. Behavioural Brain Research, 2012, 227, 194-198.	1.2	23
<b>7</b> 5	Generalization of contextual fear depends on associative rather than non-associative memory components. Behavioural Brain Research, 2012, 233, 483-493.	1.2	42
76	Assessing the Potential Clinical Utility of Transplantations of Neural and Mesenchymal Stem Cells for Treating Neurodegenerative Diseases. Methods in Molecular Biology, 2012, 879, 147-164.	0.4	19
77	Microstructural changes observed with DKI in a transgenic Huntington rat model: Evidence for abnormal neurodevelopment. Neurolmage, 2012, 59, 957-967.	2.1	59
78	Identification and characterization of Huntington related pathology: An in vivo DKI imaging study. NeuroImage, 2012, 63, 653-662.	2.1	34
79	Metabolic and electrophysiological changes in the basal ganglia of transgenic Huntington's disease rats. Neurobiology of Disease, 2012, 48, 488-494.	2.1	19
80	Motor function and dopamine release measurements in transgenic Huntington's disease model rats. Brain Research, 2012, 1450, 148-156.	1.1	29
81	Altered Hypothalamic Protein Expression in a Rat Model of Huntington's Disease. PLoS ONE, 2012, 7, e47240.	1.1	23
82	Glutaminyl Cyclase Knock-out Mice Exhibit Slight Hypothyroidism but No Hypogonadism. Journal of Biological Chemistry, 2011, 286, 14199-14208.	1.6	30
83	Genotype specific age related changes in a transgenic rat model of Huntington's disease. Neurolmage, 2011, 58, 1006-1016.	2.1	22
84	Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: Possible implications for the hypothalamic neuropeptidergic system. Behavioural Brain Research, 2011, 216, 712-718.	1.2	11
85	Altered emotional and motivational processing in the transgenic rat model for Huntington's disease. Neurobiology of Learning and Memory, 2011, 95, 92-101.	1.0	31
86	Temporal sensitivity changes with extended training in a bisection task in a transgenic rat model. Frontiers in Integrative Neuroscience, 2011, 5, 44.	1.0	16
87	Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis. Clinical and Experimental Allergy, 2011, 41, 1098-1107.	1.4	28
88	Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages. Neurobiology of Disease, 2011, 44, 192-204.	2.1	28
89	Persistent changes within the intrinsic kidney-associated NPY system and tubular function by litter size reduction. Nephrology Dialysis Transplantation, 2011, 26, 2453-2465.	0.4	12
90	Behavioral and In Vivo Electrophysiological Evidence for Presymptomatic Alteration of Prefrontostriatal Processing in the Transgenic Rat Model for Huntington Disease. Journal of Neuroscience, 2011, 31, 8986-8997.	1.7	64

#	Article	IF	CITATIONS
91	Selective Hippocampal Neurodegeneration in Transgenic Mice Expressing Small Amounts of Truncated Aβ Is Induced by Pyroglutamate–Aβ Formation. Journal of Neuroscience, 2011, 31, 12790-12801.	1.7	90
92	Stem Cell Quiescence in the Hippocampal Neurogenic Niche Is Associated With Elevated Transforming Growth Factor-Î <sup>2</sup> Signaling in an Animal Model of Huntington Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 717-728.	0.9	86
93	Dysregulation of coordinated neuronal firing patterns in striatum of freely behaving transgenic rats that model Huntington's disease. Neurobiology of Disease, 2010, 37, 106-113.	2.1	37
94	Dipeptidyl peptidase expression during experimental colitis in mice. Inflammatory Bowel Diseases, 2010, 16, 1340-1351.	0.9	44
95	Reduced airway inflammation in CD26/DPP4â€deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins. Clinical and Experimental Allergy, 2010, 40, 1794-1808.	1.4	27
96	Strumpellin is a novel valosin-containing protein binding partner linking hereditary spastic paraplegia to protein aggregation diseases. Brain, 2010, 133, 2920-2941.	3.7	62
97	Postnatal experiences influence the behavior in adult male and female Fischer and Lewis rats. International Journal of Developmental Neuroscience, 2010, 28, 561-571.	0.7	16
98	Transferred T cells preferentially adhere in the BALT of CD26-deficient recipient lungs during asthma. Immunobiology, 2010, 215, 321-331.	0.8	6
99	Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 38-45.	2.3	293
100	Neurobehavioral Tests in Rat Models of Degenerative Brain Diseases. Methods in Molecular Biology, 2010, 597, 333-356.	0.4	31
101	Serum levels of a subset of cytokines show high interindividual variability and are not altered in rats transgenic for Huntington´s disease. PLOS Currents, 2010, 2, RRN1190.	1.4	7
102	Suppression of Experimental Autoimmune Encephalomyelitis by Ghrelin. Journal of Immunology, 2009, 183, 2859-2866.	0.4	79
103	Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions. Clinical Chemistry and Laboratory Medicine, 2009, 47, 275-87.	1.4	40
104	Reduced Inflammation in CD26/DPP4-Deficient F344 Rats after OVA-Challenge Is Associated with Altered Expression of Pulmonary Surfactant Proteins, 2009, , .		0
105	CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently. Clinical and Experimental Immunology, 2009, 155, 357-365.	1.1	35
106	Airway-specific recruitment of T cells is reduced in a CD26-deficient F344 rat substrain. Clinical and Experimental Immunology, 2009, 158, 133-142.	1.1	14
107	Nicotinic acetylcholine receptor activation mediates nicotineâ€induced enhancement of experimental periodontitis. Journal of Periodontal Research, 2009, 44, 110-116.	1.4	21
108	Nicotinic acetylcholine receptor activation mediates nicotineâ€induced enhancement of experimental periodontitis. Journal of Periodontal Research, 2009, 44, 297-304.	1.4	22

#	Article	IF	Citations
109	Spontaneous <i>In Vitro</i> Transformation of Adult Neural Precursors into Stemâ€Like Cancer Cells.  Brain Pathology, 2009, 19, 399-408.	2.1	38
110	Subtle but progressive cognitive deficits in the female tgHD hemizygote rat as demonstrated by operant SILT performance. Brain Research Bulletin, 2009, 79, 310-315.	1.4	18
111	Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic α2-receptor levels in a transgenic Huntington's disease rat model. Behavioural Brain Research, 2009, 205, 175-182.	1.2	35
112	Synthetic Retinoid AM80 Inhibits Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2009, 174, 2234-2245.	1.9	84
113	Neuropeptide Y Cotransmission with Norepinephrine in the Sympathetic Nerve-Macrophage Interplay. Journal of Neurochemistry, 2008, 75, 2464-2471.	2.1	66
114	Ageâ€dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics - Clinical Applications, 2008, 2, 1638-1650.	0.8	17
115	Upâ€regulation of plateletâ€derived growth factor by peripheralâ€blood leukocytes during experimental allergic encephalomyelitis. Journal of Neuroscience Research, 2008, 86, 392-402.	1.3	23
116	Inhibition of glutaminyl cyclase prevents pGluâ€Aβ formation after intracortical/hippocampal microinjection <i>in vivo</i> / <i>in situ</i> . Journal of Neurochemistry, 2008, 106, 1225-1236.	2.1	67
117	Neuropeptide Y receptor-specifically modulates human neutrophil function. Journal of Neuroimmunology, 2008, 195, 88-95.	1.1	44
118	Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease. Journal of Neuroscience, 2008, 28, 2471-2484.	1.7	164
119	Regulation of Expression and Function of Dipeptidyl Peptidase 4 (DP4), DP8/9, and DP10 in Allergic Responses of the Lung in Rats. Journal of Histochemistry and Cytochemistry, 2008, 56, 147-155.	1.3	89
120	Impaired Regulation of Brain Mitochondria by Extramitochondrial Ca2+ in Transgenic Huntington Disease Rats. Journal of Biological Chemistry, 2008, 283, 30715-30724.	1.6	76
121	Sex differences in a transgenic rat model of Huntington's disease: decreased $17\hat{l}^2$ -estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Human Molecular Genetics, 2008, 17, 2595-2609.	1.4	114
122	Postnatal Life Events Affect the Severity of Asthmatic Airway Inflammation in the Adult Rat. Journal of Immunology, 2008, 180, 3919-3925.	0.4	37
123	Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo. Journal of Immunology, 2008, 181, 1120-1127.	0.4	101
124	Dose-dependent recruitment of CD25+ and CD26+ T cells in a novel F344 rat model of asthma. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L1564-L1571.	1.3	30
125	A role for neuropeptide Y (NPY) in phagocytosis: Implications for innate and adaptive immunity. Peptides, 2007, 28, 373-376.	1.2	56
126	Neuropeptide Y (NPY) cleaving enzymes: Structural and functional homologues of dipeptidyl peptidase 4. Peptides, 2007, 28, 257-268.	1.2	82

#	Article	IF	CITATIONS
127	2.018 Neuropathology of conditional alpha-synuclein transgenic mouse models of Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S90.	1.1	О
128	Cellular and subcellular localization of Huntington aggregates in the brain of a rat transgenic for Huntington disease. Journal of Comparative Neurology, 2007, 501, 716-730.	0.9	77
129	Dormant cancer stem cells hibernate in the mammalian brain. Journal of Stem Cells and Regenerative Medicine, 2007, 2, 175.	2.2	0
130	Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington's disease transgenic ratmodel. Behavioural Brain Research, 2006, 170, 257-261.	1.2	53
131	Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat. Brain Research Bulletin, 2006, 69, 306-310.	1.4	12
132	Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. Journal of Hepatology, 2006, 44, 512-519.	1.8	17
133	Motor and cognitive improvement by deep brain stimulation in a transgenic rat model of Huntington's disease. Neuroscience Letters, 2006, 406, 138-141.	1.0	61
134	Neuropeptide Y (NPY) modulates oxidative burst and nitric oxide production in carrageenan-elicited granulocytes from rat air pouch. Peptides, 2006, 27, 3208-3215.	1.2	32
135	Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the anti-depressant tianeptine. Journal of Clinical Periodontology, 2006, 33, 469-477.	2.3	50
136	Age-related effect of peptide YY (PYY) on paw edema in the rat: The function of Y1 receptors on inflammatory cells. Experimental Gerontology, 2006, 41, 793-799.	1.2	18
137	Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. Neurobiology of Disease, 2006, 22, 538-547.	2.1	65
138	Stress-induced hyperthermia in the rat: comparison of classical and novel recording methods. Laboratory Animals, 2006, 40, 186-193.	0.5	51
139	A Mutation in Aminopeptidase N (CD13) Isolated from a Patient Suffering from Leukemia Leads to an Arrest in the Endoplasmic Reticulum. Journal of Biological Chemistry, 2006, 281, 11894-11900.	1.6	9
140	Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Human Molecular Genetics, 2006, 15, 3177-3194.	1.4	109
141	Early Postnatal Nongenetic Factors Modulate Disease Susceptibility in Adulthood: Examples from Disease Models of Multiple Sclerosis, Periodontitis, and Asthma. , 2006, , 241-254.		0
142	Intestinal Apical Protein Transport in Health and Disease., 2006,, 315-338.		0
143	Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation. Journal of Neurochemistry, 2005, 94, 639-650.	2.1	53
144	CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clinical and Experimental Immunology, 2005, 139, 17-24.	1.1	62

#	Article	IF	Citations
145	Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors. Regulatory Peptides, 2005, 124, 163-172.	1.9	53
146	NPY, NPY receptors and DPPIV in innate immunity and autoimmune disorders. , 2005, , 87-106.		0
147	Y1 receptors regulate aggressive behavior by modulating serotonin pathways. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12742-12747.	3.3	83
148	Neuropeptide Y stabilizes body temperature and prevents hypotension in endotoxaemic rats. Journal of Physiology, 2004, 561, 245-252.	1.3	35
149	Reduced tissue immigration of monocytes by neuropeptide Y during endotoxemia is associated with Y2 receptor activation. Journal of Neuroimmunology, 2004, 155, 1-12.	1.1	54
150	Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. Regulatory Peptides, 2004, 120, 205-214.	1.9	36
151	More sympathy for autoimmunity with neuropeptide Y?. Trends in Immunology, 2004, 25, 508-512.	2.9	62
152	Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Human Pathology, 2004, 35, 113-121.	1.1	45
153	NPY and Immune Functions: Implications for Health and Disease. Handbook of Experimental Pharmacology, 2004, , 409-445.	0.9	1
154	PP, PYY and NPY: Synthesis, Storage, Release and Degradation. Handbook of Experimental Pharmacology, 2004, , 23-44.	0.9	13
155	CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26. Cancer Immunology, Immunotherapy, 2003, 52, 546-554.	2.0	38
156	Behavioral phenotyping of mice in pharmacological and toxicological research. Experimental and Toxicologic Pathology, 2003, 55, 69-83.	2.1	280
157	Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacology Biochemistry and Behavior, 2003, 75, 869-879.	1.3	45
158	Relevance of Neuropeptide Y for the neuroimmune crosstalk. Journal of Neuroimmunology, 2003, 134, 1-11.	1.1	130
159	Neuropeptide Y (NPY) Suppresses Experimental Autoimmune Encephalomyelitis: NPY1 Receptor-Specific Inhibition of Autoreactive Th1 Responses In Vivo. Journal of Immunology, 2003, 171, 3451-3458.	0.4	103
160	Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiology and Behavior, 2003, 80, 123-134.	1.0	55
161	Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats. Regulatory Peptides, 2003, 115, 81-90.	1.9	46
162	Transgenic rat model of Huntington's disease. Human Molecular Genetics, 2003, 12, 617-624.	1.4	329

#	Article	IF	Citations
163	Intratracheal Macrophage-Activating Lipopeptide-2 Reduces Metastasis in the Rat Lung. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 316-321.	1.4	26
164	Postnatal Lipopolysaccharide-Induced Illness Predisposes to Periodontal Disease in Adulthood. Brain, Behavior, and Immunity, 2002, 16, 421-438.	2.0	87
165	Postnatal maternal deprivation aggravates experimental autoimmune encephalomyelitis in adult Lewis rats: reversal by chronic imipramine treatment. International Journal of Developmental Neuroscience, 2002, 20, 125-132.	0.7	27
166	Postnatally induced differences in adult pain sensitivity depend on genetics, gender and specific experiences: reversal of maternal deprivation effects by additional postnatal tactile stimulation or chronic imipramine treatment. Behavioural Brain Research, 2002, 133, 149-158.	1.2	41
167	Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). Journal of Neuroimmunology, 2002, 129, 35-42.	1.1	46
168	NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization. Journal of Neuroimmunology, 2002, 132, 25-33.	1.1	43
169	Kinetics of the early recruitment of leukocyte subsets at the sites of tumor cells in the lungs: Natural killer (NK) cells rapidly attract monocytes but not lymphocytes in the surveillance of micrometastasis. International Journal of Cancer, 2002, 99, 74-81.	2.3	30
170	The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neuroscience and Biobehavioral Reviews, 2002, 26, 259-283.	2.9	316
171	Neuropeptide YY1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience, 2001, 104, 799-806.	1.1	78
172	Factors influencing behavior of group-housed male rats in the social interaction test. Physiology and Behavior, 2001, 74, 277-282.	1.0	38
173	Hypothalamic-pituitary-adrenal axis activation by experimental periodontal disease in rats. Journal of Periodontal Research, 2001, 36, 295-300.	1.4	41
174	Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. Journal of Neuroimmunology, 2001, 117, 125-132.	1.1	58
175	Conditioned Alterations of Specific Blood Leukocyte Subsets Are Reconditionable. NeuroImmunoModulation, 2000, 7, 106-114.	0.9	15
176	Stereological quantification of carboxyfluorescein-labeled rat lung metastasis: a new method for the assessment of natural killer cell activity and tumor adhesion in vivo and in situ. Journal of Immunological Methods, 2000, 239, 25-34.	0.6	25
177	Use of cryostat sections from snap-frozen nervous tissue for combining stereological estimates with histological, cellular, or molecular analyses on adjacent sections. Journal of Chemical Neuroanatomy, 2000, 20, 21-29.	1.0	23
178	Leukocyte mobilization induced by hypervolemia is due to a combined alpha- and beta-adrenoceptor activation. Comparative Medicine, 2000, 50, 495-7.	0.4	4
179	Brain NPY Y1 receptors rapidly mediate the behavioral response to novelty and a compartment-specific modulation of granulocyte function in blood and spleen. Brain Research, 1998, 806, 282-286.	1.1	38
180	Cyclosporine A Affects Open Field Behavior in DA Rats. Pharmacology Biochemistry and Behavior, 1998, 60, 71-76.	1.3	42

#	Article	IF	CITATIONS
181	Behaviorally conditioned effects of Cyclosporine A on the immune system of rats: specific alterations of blood leukocyte numbers and decrease of granulocyte function. Journal of Neuroimmunology, 1998, 85, 193-201.	1.1	27
182	Behaviorally conditioned immunosuppression using cyclosporine A: central nervous system reduces IL-2 production via splenic innervation. Journal of Neuroimmunology, 1998, 88, 182-191.	1.1	81
183	Modulation of innate immune functions by intracerebroventricularly applied neuropeptide Y: Dose and time dependent effects. Life Sciences, 1998, 63, 909-922.	2.0	42
184	Conditioned Taste Aversion Produced by Cyclosporine A: Concomitant Reduction in Lymphoid Organ Weight and Splenocyte Proliferation. Physiology and Behavior, 1998, 63, 241-247.	1.0	27
185	Centrally applied NPY mimics immunoactivation induced by non-analgesic doses of met-enkephalin. NeuroReport, 1998, 9, 3881-3885.	0.6	25
186	Experimental allergic encephalomyelitis in adult DA rats subjected to neonatal handling or gentling. Brain Research, 1995, 676, 133-140.	1.1	40
187	Opioid receptor-mediated suppression of humoral immune response in vivo and in vitro: involvement of $\hat{l}^2$ opioid receptors. Journal of Neuroimmunology, 1995, 57, 55-62.	1.1	47
188	Neonatal Sound Stress and Development of Experimental Allergic Encephalomyelitis in Lewis and Da Rats. International Journal of Neuroscience, 1994, 78, 135-143.	0.8	19
189	Effect of early experience on behavior and immune response in the rat. Physiology and Behavior, 1993, 54, 931-940.	1.0	76